-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In order to improve and develop China's medical manufacturing outsourcing (CMO) business, in recent years, the country has issued many policies and regulations
.
At the same time, driven by multiple forces, the development of China's pharmaceutical outsourcing industry has been continuously promoted
.
According to Frost&Sullivan's data, in 2020, China's medical manufacturing outsourcing (CMO) market will be approximately 4 billion U.
S.
dollars
.
From the company's point of view, racing against time is the core value of new drug research and development
.
The outsourcing service platform not only allows pharmaceutical companies to focus on their main business, but also saves time and financial costs
.
It is understood that in Shanghai, Suzhou and other places, China's outsourcing service platform utilization rate is as high as 90% in the research and development of new drugs
.
According to data from the China Medical Information Association, in the first half of this year, outsourcing services contributed 35% of the new drugs approved in China
.
Pharmaceutical outsourcing services have become an accelerator for the approval of new drugs in China
.
In addition, Frost & Sullivan predicts that from 2021 to 2026, the scale of the global outsourcing service market (excluding macromolecule CDMO) provided by China Pharmaceutical R&D Service Corporation will grow from 98.
5 billion RMB to 300.
6 billion RMB, an average annual increase of approximately 25 %
.
The so-called medical R&D outsourcing is a kind of commercial academic scientific institution that provides professional services for pharmaceutical companies and R&D institutions in the process of drug research and invention through contracts
.
It is understood that the previous pharmaceutical R&D outsourcing industry only served one of the links of generic drugs or innovative drugs.
Nowadays, with the increasingly fierce competition, pharmaceutical R&D outsourcing companies can basically contract all aspects of drug R&D
.
At present, my country’s major pharmaceutical manufacturing outsourcing (CMO) companies include Kailaiying, Proton, Yaoshi Technology, Jiuzhou Pharmaceutical, Kanglong Chemical, Prologue, Lianhua Technology, Tianyu, Haixiang Pharmaceutical, Haoyuan Pharmaceutical, Wise Pharmaceutical, WuXi AppTec, etc.
.
Among them, Kailaiying stated in the recent prospectus that as of the third quarter of 2021, the company has cooperated with 15 of the world’s top 20 pharmaceutical factories, 8 of which have been cooperating continuously for more than ten years.
The company has also cooperated with many biotechnology and Cooperation with small and medium-sized pharmaceutical companies
.
According to Kailaiying, the company has now expanded its CDMO capabilities to include new drug categories, such as peptides, oligonucleotides, monoclonal antibodies (mAb), etc.
, as well as pharmaceutical preparations, biosynthesis and clinical CRO solutions
.
The data shows that in the past three years, all data of Gloria have been increasing steadily
.
In terms of revenue, it reached 1.
82 billion yuan in 2018, 2.
45 billion yuan in 2019, and 3.
14 billion yuan in 2020.
From 2018 to 2020, its revenue has a compound annual growth rate of more than 31%
.
In addition, the prospectus shows that the US market accounted for the majority of Calais’s revenue in the past three years, accounting for 83% at one time
.
WuXi AppTec, another representative company in pharmaceutical manufacturing outsourcing (CMO), has established 32 branches worldwide by 2020, providing services to more than 4,200 customers from more than 30 countries around the world (active Customer)
.
The data shows that WuXi AppTec's overseas revenue has been increasing year by year in recent years.
From 2017 to 2020, the company's overseas revenue has risen from 6.
609 billion yuan to 12.
39 billion yuan
.
In the first half of 2021, the company's overseas revenue was 8.
036 billion yuan, accounting for 76.
3%
.
Analysts pointed out that compared with European and American countries, China's pharmaceutical outsourcing service companies have advantages in labor costs and economies of scale, and R&D costs can be reduced by about 50%.
Therefore, some well-known international pharmaceutical companies have also transferred some outsourcing service orders to China.
.
This has also promoted the layout of China's pharmaceutical outsourcing companies in the global market to a certain extent
.
At present, the pharmaceutical and health industry is entering a golden age.
Knowledge and data are integrated, and technology and medical treatment are integrated.
The future new drug research and development model will usher in a new definition and far-reaching change, and the pharmaceutical outsourcing service industry will also usher in new development opportunities.
.
"Seize new business opportunities and empower global pharmaceutical innovation.
" Many Chinese pharmaceutical outsourcing service companies stated that they will continue to invest heavily to strengthen their service capabilities
.
.
At the same time, driven by multiple forces, the development of China's pharmaceutical outsourcing industry has been continuously promoted
.
According to Frost&Sullivan's data, in 2020, China's medical manufacturing outsourcing (CMO) market will be approximately 4 billion U.
S.
dollars
.
From the company's point of view, racing against time is the core value of new drug research and development
.
The outsourcing service platform not only allows pharmaceutical companies to focus on their main business, but also saves time and financial costs
.
It is understood that in Shanghai, Suzhou and other places, China's outsourcing service platform utilization rate is as high as 90% in the research and development of new drugs
.
According to data from the China Medical Information Association, in the first half of this year, outsourcing services contributed 35% of the new drugs approved in China
.
Pharmaceutical outsourcing services have become an accelerator for the approval of new drugs in China
.
In addition, Frost & Sullivan predicts that from 2021 to 2026, the scale of the global outsourcing service market (excluding macromolecule CDMO) provided by China Pharmaceutical R&D Service Corporation will grow from 98.
5 billion RMB to 300.
6 billion RMB, an average annual increase of approximately 25 %
.
The so-called medical R&D outsourcing is a kind of commercial academic scientific institution that provides professional services for pharmaceutical companies and R&D institutions in the process of drug research and invention through contracts
.
It is understood that the previous pharmaceutical R&D outsourcing industry only served one of the links of generic drugs or innovative drugs.
Nowadays, with the increasingly fierce competition, pharmaceutical R&D outsourcing companies can basically contract all aspects of drug R&D
.
At present, my country’s major pharmaceutical manufacturing outsourcing (CMO) companies include Kailaiying, Proton, Yaoshi Technology, Jiuzhou Pharmaceutical, Kanglong Chemical, Prologue, Lianhua Technology, Tianyu, Haixiang Pharmaceutical, Haoyuan Pharmaceutical, Wise Pharmaceutical, WuXi AppTec, etc.
.
Among them, Kailaiying stated in the recent prospectus that as of the third quarter of 2021, the company has cooperated with 15 of the world’s top 20 pharmaceutical factories, 8 of which have been cooperating continuously for more than ten years.
The company has also cooperated with many biotechnology and Cooperation with small and medium-sized pharmaceutical companies
.
According to Kailaiying, the company has now expanded its CDMO capabilities to include new drug categories, such as peptides, oligonucleotides, monoclonal antibodies (mAb), etc.
, as well as pharmaceutical preparations, biosynthesis and clinical CRO solutions
.
The data shows that in the past three years, all data of Gloria have been increasing steadily
.
In terms of revenue, it reached 1.
82 billion yuan in 2018, 2.
45 billion yuan in 2019, and 3.
14 billion yuan in 2020.
From 2018 to 2020, its revenue has a compound annual growth rate of more than 31%
.
In addition, the prospectus shows that the US market accounted for the majority of Calais’s revenue in the past three years, accounting for 83% at one time
.
WuXi AppTec, another representative company in pharmaceutical manufacturing outsourcing (CMO), has established 32 branches worldwide by 2020, providing services to more than 4,200 customers from more than 30 countries around the world (active Customer)
.
The data shows that WuXi AppTec's overseas revenue has been increasing year by year in recent years.
From 2017 to 2020, the company's overseas revenue has risen from 6.
609 billion yuan to 12.
39 billion yuan
.
In the first half of 2021, the company's overseas revenue was 8.
036 billion yuan, accounting for 76.
3%
.
Analysts pointed out that compared with European and American countries, China's pharmaceutical outsourcing service companies have advantages in labor costs and economies of scale, and R&D costs can be reduced by about 50%.
Therefore, some well-known international pharmaceutical companies have also transferred some outsourcing service orders to China.
.
This has also promoted the layout of China's pharmaceutical outsourcing companies in the global market to a certain extent
.
At present, the pharmaceutical and health industry is entering a golden age.
Knowledge and data are integrated, and technology and medical treatment are integrated.
The future new drug research and development model will usher in a new definition and far-reaching change, and the pharmaceutical outsourcing service industry will also usher in new development opportunities.
.
"Seize new business opportunities and empower global pharmaceutical innovation.
" Many Chinese pharmaceutical outsourcing service companies stated that they will continue to invest heavily to strengthen their service capabilities
.
